secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001140361-24-025476
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocuphire Pharma presents NPDR subset analysis from ZETA-1 Phase 2 trial for APX3330
--------------------------------------------------------------------------------

- Subset analysis: 3% of APX3330 vs 20% of placebo had ≥3-step worsening on binocular DRSS at Week 24.
- 7% of APX3330 vs 27% of placebo developed PDR (DRSS ≥61) in either eye at Week 24.
- APX3330 was well-tolerated; ocular AEs similar between groups, pruritus mild/self-limited.
- NPDR subset includes moderate-to-severe NPDR patients without CI-DME at baseline.
- Results inform planned trial of APX3330 to slow PDR conversion in high-risk NPDR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124025476/0001140361-24-025476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036124025476/ef20028889_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-025476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer